BrightInsight Secures Multi-Million Dollar Investment To Accelerate Its AI-Powered Medication Persistence & Adherence Solutions

BrightInsight, Inc., a leading company in digital health technology, has announced that it has secured a new investment of $13 million from both existing and new investors. The round included Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. This additional funding will help the company speed up the development of its AI-powered solutions that support medication persistence and adherence. It will also allow BrightInsight to scale successful programs more quickly, such as the Patient App developed through its collaboration with Sanofi and its partner, Regeneron, and expand these efforts across more diseases and treatments worldwide.

Medication non-adherence remains one of the most urgent and overlooked problems in global healthcare. Even with access to life-saving therapies, adherence rates for chronic conditions remain at approximately 50 percent. This gap leads to around 125,000 preventable deaths every year and contributes to as much as 25 percent of hospitalizations in the United States. The financial impact is also severe, as non-adherence generates an estimated $100 billion to $300 billion annually in avoidable healthcare costs, including unnecessary doctor visits, emergency care, and extended hospital stays.

BrightInsight aims to address this issue by offering digital solutions that help patients stay on their prescribed therapies, improving health outcomes while reducing the burden on healthcare systems. According to Kal Patel, CEO and Co-Founder of BrightInsight, the company typically sees 30 to 70 percent of invited patients joining its programs, with a similar percentage continuing to use these tools one year later. These results have been consistent across different diseases and patient groups.

Vijay Lathi, Managing Director at New Leaf Venture Partners, said that the firm’s continued investment reflects the strong progress BrightInsight has made. He noted that the company has demonstrated its ability to scale a platform that solves a critical market need and that its measurable impact on patient support made the decision to reinvest clear.

With this new capital, BrightInsight plans to accelerate its product roadmap by integrating AI throughout the platform to deliver personalized insights and predictions, such as identifying patients at risk of discontinuing medication. The company also intends to broaden its network of disease-area partners and enhance support for additional stakeholders, including caregivers and nurse educators.

Robert Zdon, Chief Operating Officer at BrightInsight, emphasized that patient engagement and medication adherence remain some of the most persistent challenges in healthcare. He explained that the real-world data generated through the BrightInsight platform is reshaping how treatments are supported, and that applying advanced AI to this data can help predict medication churn and deliver interventions tailored to individual patients to improve long-term outcomes. The announcement highlights BrightInsight’s continued commitment to addressing one of healthcare’s most significant challenges through scalable, data-driven digital solutions.